RPHM Stock Overview
A clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Reneo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.61 |
| 52 Week High | US$9.21 |
| 52 Week Low | US$0.98 |
| Beta | 0.23 |
| 11 Month Change | -3.01% |
| 3 Month Change | -2.42% |
| 1 Year Change | -75.61% |
| 33 Year Change | -82.78% |
| 5 Year Change | n/a |
| Change since IPO | -88.41% |
Recent News & Updates
Recent updates
We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Oct 03
Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth
Apr 25Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Nov 22We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Aug 09Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Apr 22We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth
Jan 20Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation
Oct 02Our First Look At Reneo Pharmaceuticals
Aug 15Shareholder Returns
| RPHM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | 2.0% | -0.3% |
| 1Y | -75.6% | 12.4% | 22.3% |
Return vs Industry: RPHM underperformed the US Biotechs industry which returned 12% over the past year.
Return vs Market: RPHM underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| RPHM volatility | |
|---|---|
| RPHM Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RPHM has not had significant price volatility in the past 3 months.
Volatility Over Time: RPHM's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 8 | Greg Flesher | reneopharma.com |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company’s lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals, Inc. Fundamentals Summary
| RPHM fundamental statistics | |
|---|---|
| Market cap | US$54.14m |
| Earnings (TTM) | -US$70.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs RPHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPHM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$70.71m |
| Earnings | -US$70.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RPHM perform over the long term?
See historical performance and comparison